Search Articles — Sudonull

https://sudonull.com/loot-boxes-for-children-restrictions-in-russia

Deputy Milonov proposed restricting loot boxes for minors. We analyze the essence of the initiative, international experience, and possible consequences for the gaming industry.

https://sudonull.com/chinese-exoskeleton-0-96-kg-treatment-of-muscle-atrophy-from-nature

Chinese exoskeleton weighing 0.96 kg treats muscular dystrophy, not replaces function. Nature results: children stood up without the device. Find out how this changes the market.

https://ymaho.com/impact-of-plant-based-diets-on-children-s-health-analysis-of-59-studies

A meta-analysis of 59 studies showed that veganism and vegetarianism are safe for children when controlling for deficiencies of B12, iron, and calcium. Learn about the risks and benefits of plant-based nutrition.

https://ymaho.com/repeated-covid-in-children-risk-of-long-covid-twice-as-high

Repeated COVID-19 in children increases the risk of long COVID by 2 times: myocarditis, thrombosis, cognitive impairment. Learn about the risks and protect your child.

https://ymaho.com/tzield-approved-for-children-from-1-year-delaying-type-1-diabetes

FDA expanded indications for teplizumab to children from one year. First drug capable of delaying diabetes for years at the preclinical stage. Learn how infusions change the prognosis for infants.

https://ymaho.com/teplizumab-approved-for-children-delaying-type-1-diabetes

FDA approved teplizumab for children from 1 year old. Learn how disease-modifying therapy changes the treatment paradigm for type 1 diabetes. Detailed analysis.

https://ymaho.com/crispr-gene-therapy-for-children-with-anemia-ema-approval-2026

EMA approved CASGEVY for children 5-11 years with sickle cell anemia. 100% efficacy, price 1.8 million EUR. Risks and benefits — in the analysis. Learn more.

https://ymaho.com/fda-to-review-inhaled-insulin-afrezza-for-children

On May 29, FDA will decide on needle-free insulin Afrezza for children aged 4–17. Learn why this is a paradigm shift in diabetology. Detailed analysis in the article.

https://ymaho.com/ema-accepted-the-application-for-dovato-for-children-with-hiv

EMA validated the application for the use of Dovato in children from 3 months with HIV. Learn how this will change pediatric therapy and strengthen ViiV's position. Read the detailed analysis.

https://ymaho.com/fda-approved-first-gene-therapy-for-lad-i-in-children

FDA approved Kresladi (marnetegragene autotemcel) — the first stem cell gene therapy for children with severe LAD-I. Learn about the mechanism, precedents, and business model. Detailed analysis on the website.

https://ymaho.com/fda-to-review-afrezza-first-needle-free-insulin-for-children

On May 29, 2026, the FDA will decide on Afrezza inhaled insulin for children aged 4–17. Learn why this is a market shift and a chance for a needle-free life. Read the analysis.

https://ymaho.com/fda-to-review-ctx-1301-for-adhd-treatment-in-children

New CTx-1301 with trimodal release provides ADHD symptom control for up to 12 hours. Learn about the FDA decision and PTR technology.